Mono Pharmacare Limited

NSEI:MONOPHARMA Stok Raporu

Piyasa değeri: ₹602.5m

Mono Pharmacare Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 4/6

Mono Pharmacare has been growing earnings at an average annual rate of 52.9%, while the Healthcare industry saw earnings growing at 29.2% annually. Revenues have been growing at an average rate of 42% per year. Mono Pharmacare's return on equity is 8.7%, and it has net margins of 2%.

Anahtar bilgiler

52.9%

Kazanç büyüme oranı

42.7%

EPS büyüme oranı

Healthcare Sektör Büyümesi29.4%
Gelir büyüme oranı42.0%
Özkaynak getirisi8.7%
Net Marj2.0%
Son Kazanç Güncellemesi31 Mar 2024

Yakın geçmiş performans güncellemeleri

Güncelleme yok

Recent updates

We Think Mono Pharmacare (NSE:MONOPHARMA) Is Taking Some Risk With Its Debt

Sep 26
We Think Mono Pharmacare (NSE:MONOPHARMA) Is Taking Some Risk With Its Debt

Market Still Lacking Some Conviction On Mono Pharmacare Limited (NSE:MONOPHARMA)

Aug 11
Market Still Lacking Some Conviction On Mono Pharmacare Limited (NSE:MONOPHARMA)

Gelir ve Gider Dağılımı

Mono Pharmacare nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.


Kazanç ve Gelir Geçmişi

NSEI:MONOPHARMA Gelir, gider ve kazançlar (INR Millions )
TarihGelirKazançlarG+A GiderleriAr-Ge Giderleri
31 Mar 241,22424350
31 Dec 2395024320
30 Sep 2376222260
30 Jun 2354716180
31 Mar 233319100
31 Mar 22371470
31 Mar 21284170
31 Mar 201170100

Kaliteli Kazançlar: MONOPHARMA has high quality earnings.

Büyüyen Kar Marjı: MONOPHARMA's current net profit margins (2%) are lower than last year (2.8%).


Serbest Nakit Akışı ve Kazanç Analizi


Geçmiş Kazanç Büyüme Analizi

Kazanç Eğilimi: MONOPHARMA's earnings have grown significantly by 52.9% per year over the past 5 years.

Büyüme Hızlandırma: MONOPHARMA's earnings growth over the past year (158.8%) exceeds its 5-year average (52.9% per year).

Kazançlar vs. Sektör: MONOPHARMA earnings growth over the past year (158.8%) exceeded the Healthcare industry 30.6%.


Özkaynak Getirisi

Yüksek ROE: MONOPHARMA's Return on Equity (8.7%) is considered low.


Varlık Getirisi


Kullanılan Sermaye Getirisi


Geçmişte güçlü performans gösteren şirketleri keşfedin